Central Trust Company’s Accentia Biopharmaceuticals ABPI Stock Holding History

Central Trust Company’s Portfolio ABPI Stock Details ABPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-7,375	Closed	–	–	1372
2017 Q1	$0	Hold	7,375	–	–	﹤0.01%	1255
2016 Q4	$0	Hold	7,375	–	–	﹤0.01%	1239
2016 Q3	$0	Hold	7,375	–	–	﹤0.01%	1232
2016 Q2	$0	Hold	7,375	–	–	﹤0.01%	1206
2016 Q1	$0	Hold	7,375	–	–	﹤0.01%	1227
2015 Q4	$0	Hold	7,375	–	–	﹤0.01%	1261
2015 Q3	$0	Hold	7,375	–	–	﹤0.01%	1302
2015 Q2	$0	Hold	7,375	–	–	﹤0.01%	1271
2015 Q1	$0	Hold	7,375	–	–	﹤0.01%	1258
2014 Q4	$0	Hold	7,375	–	–	﹤0.01%	1277
2014 Q3	$0	Hold	7,375	–	–	﹤0.01%	1248
2014 Q2	$0	Hold	7,375	–	–	﹤0.01%	1248
2014 Q1	$0	Hold	7,375	–	–	﹤0.01%	1272
2013 Q4	$0	Sell	7,375 -7,000	-49%	–	﹤0.01%	1230
2013 Q3	$0	Hold	14,375	–	–	﹤0.01%	1194
2013 Q2	$0	Buy	+14,375	New	–	﹤0.01%	1102

Central Trust Company's ABPI Position: Q2 2017 in Review

Central Trust Company sold out of Accentia Biopharmaceuticals (ABPI) in Q2 2017, closing a stake of 7,375 shares.

Central Trust Company first reported a position in ABPI in Q2 2013 and held it in 16 quarters. The position peaked at $0 in Q1 2017. 1 fund tracked by Wall St. Rank holds ABPI as of Q2 2017.

Central Trust Company reported no remaining Accentia Biopharmaceuticals position as of Q2 2017 after selling out during the quarter.
Central Trust Company sold 7,375 Accentia Biopharmaceuticals shares in Q2 2017.
Central Trust Company first reported a position in Accentia Biopharmaceuticals in Q2 2013 and held it in 16 quarters.
Central Trust Company's Accentia Biopharmaceuticals position peaked at $0 in Q1 2017.
1 fund tracked by Wall St. Rank held Accentia Biopharmaceuticals as of Q2 2017.

Based on Central Trust Company's 13F filing for Q2 2017, filed 14 Jul 2017.